IMMUNIC, INC. Logo

IMMUNIC, INC.

Develops oral small molecule therapies for chronic inflammatory and autoimmune diseases.

IMUX | US

Overview

Corporate Details

ISIN(s):
US4525EP1011 (+1 more)
LEI:
549300R5T12FW5MEQB20
Country:
United States of America
Address:
1200 AVENUE OF THE AMERICAS, 10036 NEW YORK

Description

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's mission is to create high-quality, oral treatment options that offer comprehensive therapeutic efficacy with favorable safety and tolerability profiles. Its clinical development programs target conditions with significant unmet medical needs, including multiple sclerosis and celiac disease, aiming to provide patients with convenient and effective solutions to manage debilitating symptoms and improve their quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-26 12:30
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in…
English 9.9 KB
2025-11-13 12:30
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corpora…
English 22.9 KB
2025-10-29 11:30
Immunic to Participate in Industry and Investor Conferences in November
English 9.7 KB
2025-10-01 12:30
Immunic to Participate in Scientific and Investor Conferences in October
English 14.9 KB
2025-09-25 12:30
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS…
English 23.6 KB
2025-09-09 12:30
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofl…
English 13.9 KB
2025-09-04 12:30
Immunic to Participate in Investor and Scientific Conferences in September
English 15.6 KB
2025-08-07 12:30
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corpor…
English 23.5 KB
2025-06-24 12:30
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 …
English 15.2 KB
2025-06-05 12:30
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Re…
English 18.3 KB
2025-06-02 12:30
Immunic to Participate in Investor, Scientific and Industry Conferences in June
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all IMMUNIC, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IMMUNIC, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IMMUNIC, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.